Msac application 1173



Yüklə 2,13 Mb.
səhifə18/25
tarix07.01.2022
ölçüsü2,13 Mb.
#89204
1   ...   14   15   16   17   18   19   20   21   ...   25

Safety


 Toxic effects from subsequent treatment (including skin rash, diarrhoea, thrombocytopenia)

 Adverse events associated with biopsies

Rate of re-biopsy

Summary of PICO to be used for assessment of evidence (systematic review)

Table 3 provides a summary of the PICO used to: (1) define the question for public funding,



(2) select the evidence to assess the safety and effectiveness of EGFR gene mutation

testing, with erlotinib and

(3) provide the evidence-based inputs for any decision-analysis modelling to determine the cost-effectiveness of EGFR gene mutation testing with erlotinib.
Table 3: Summary of PICO to define the question for public funding that assessment will investigate



Yüklə 2,13 Mb.

Dostları ilə paylaş:
1   ...   14   15   16   17   18   19   20   21   ...   25




Verilənlər bazası müəlliflik hüququ ilə müdafiə olunur ©muhaz.org 2024
rəhbərliyinə müraciət

gir | qeydiyyatdan keç
    Ana səhifə


yükləyin